Total: $144.02M

Company
(Symbol)#

Type Of
Financing

Number
Of Shares, Units Or Warrants (M)

Amount
Raised
(M)

Investors; Placement Agents; Details (Date)@


Aastrom
Biosciences Inc.
(ASTM)

Private placement of common stock

3.3S

$5

Aastrom placed a total of 3.3M shares during August with Isosceles Fund Ltd., raising $5M (8/27)

Antex Biologics Inc. (AMEX:
ANX)

Private placement of convertible preferred stock and warrants

N/A

$3

Antex raised $3M in a private placement managed by H.C. Wainwright & Co. Inc.; investors included Xmark LP and Xmark Ltd., both managed by Brown Simpson Asset Management, SDS Merchant Fund LP and S.A.C. Capital Associates LLC (8/1)

Aphton Corp.
(APHT)

Private placement of common stock

1.2S

$14.25

Aphton raised $14.25M in a private equity financing with several institutional investors, selling about 1.2M shares of common stock at $12 per share (8/27)

Aradigm Corp. (ARDM)

Private placement of common stock and warrants

3.6S and 0.36W

$14.6

Aradigm raised $14.6M selling about 3.6M shares and warrants to purchase 363,929 shares (8/23)

BioTime Inc.
(AMEX:BTX)

Private placement of 10% nonconvertible debentures and warrants

N/A

$3.5

BioTime raised $3.5M through the private placement (8/23)

Hyseq Inc.
(HYSQ)

Private placement of common stock

3.04S

$21.3

Hyseq raised $21.3M in a private placement that included Narragansett Asset Management, Vulcan Ventures and senior Hyseq management and board members led by George Rathmann, chairman (8/30)

Incara
Pharmaceuticals
Corp.
(INCR)

Private placement of common stock and warrants

4.25S and 1W

$7

Incara raised $7M in an offering of 4.25M shares and warrants to purchase about 1M shares; investors included Deerfield Capital Management, Merlin Biomed Asset Management and other institutional and private investors; Petkevich & Partners LLC was placement agent (8/10)

Neotherapeutics
Inc.
(NEOT)

Private placement of common stock

0.6S

$2.01M

Neotherapeutics placed 600,000 shares with Summit Capital Management LLC, raising $2.01M (8/14)

Ortec
International
Inc.
(ORTC)

Financing for non-equity capital

N/A

$25

Ortec completed the financing with Paul Capital Royalty Acquisition Fund for up to $25M (8/30)

Synaptic
Pharmaceutical
Corp.
(SNAP)

Private placement of convertible preferred stock

2.2S

$9.4

Synaptic raised $9.4M in the first part of a two-part financing; Warburg Pincus & Co. LLC bought the Series B preferred stock, which is convertible into 2.2M shares; the second part of the financing involves Warburg's purchase of as much as $1.6M worth of Series B preferred stock and $30M worth of Series C preferred stock (8/3)

Triangle
Pharmaceuticals
Inc.
(VIRS)

Private placement of common stock

9.62S

$25.51

Triangle raised $25.51M in its first closing of a two-part financing to sell 28.3M shares to Warburg Pincus Private Equity VIII LP for $2.65 per share; the second closing is expected to occur in a little over a month; Bank of America Securities LLC is serving as placement agent (8/24)

ViroLogic Inc.
(VLGC)

Private placement of warrants

3.2W

$9.55

ViroLogic raised $9.55M in the second portion of a $16.25M private placement; the first portion, totaling about $6.7M, closed July 2 (8/30)

Viventia Biotech
Inc.
(Canada;
TSE:VBI)

Private placement of units

17.9U

C$6 (US$3.9)

Dan Family Holdings Ltd. purchased the units, which each includes one common share and one purchase warrant to buy a common share at 33.5 cents for up to five years (8/27)


Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

@ Dates refer to the date of the press release.

N/A = Not available or reported.

AMEX = American Stock Exchange; TSE = Toronto Stock Exchange

No Comments